Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells.

Bonnet M, Flanagan JU, Chan DA, Lai EW, Nguyen P, Giaccia AJ, Hay MP.

Bioorg Med Chem. 2011 Jun 1;19(11):3347-56. doi: 10.1016/j.bmc.2011.04.042. Epub 2011 Apr 24.

2.

4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death.

Hay MP, Turcotte S, Flanagan JU, Bonnet M, Chan DA, Sutphin PD, Nguyen P, Giaccia AJ, Denny WA.

J Med Chem. 2010 Jan 28;53(2):787-97. doi: 10.1021/jm901457w.

3.
4.

A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.

Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, Giaccia AJ.

Cancer Cell. 2008 Jul 8;14(1):90-102. doi: 10.1016/j.ccr.2008.06.004.

5.

Identifying novel targets in renal cell carcinoma: design and synthesis of affinity chromatography reagents.

Bonnet M, Flanagan JU, Chan DA, Giaccia AJ, Hay MP.

Bioorg Med Chem. 2014 Jan 15;22(2):711-20. doi: 10.1016/j.bmc.2013.12.028. Epub 2013 Dec 20.

PMID:
24387866
6.

Identification of the Lipodepsipeptide MDN-0066, a Novel Inhibitor of VHL/HIF Pathway Produced by a New Pseudomonas Species.

Cautain B, de Pedro N, Schulz C, Pascual J, Sousa Tda S, Martin J, Pérez-Victoria I, Asensio F, González I, Bills GF, Reyes F, Genilloud O, Vicente F.

PLoS One. 2015 May 27;10(5):e0125221. doi: 10.1371/journal.pone.0125221. eCollection 2015.

7.

Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.

Perier A, Fregni G, Wittnebel S, Gad S, Allard M, Gervois N, Escudier B, Azzarone B, Caignard A.

Oncogene. 2011 Jun 9;30(23):2622-32. doi: 10.1038/onc.2010.638. Epub 2011 Jan 24.

PMID:
21258414
8.

Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells.

Sutphin PD, Chan DA, Li JM, Turcotte S, Krieg AJ, Giaccia AJ.

Cancer Res. 2007 Jun 15;67(12):5896-905.

9.

Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.

Yuen JS, Akkaya E, Wang Y, Takiguchi M, Peak S, Sullivan M, Protheroe AS, Macaulay VM.

Mol Cancer Ther. 2009 Jun;8(6):1448-59. doi: 10.1158/1535-7163.MCT-09-0101. Epub 2009 Jun 9.

10.

Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.

Leisz S, Schulz K, Erb S, Oefner P, Dettmer K, Mougiakakos D, Wang E, Marincola FM, Stehle F, Seliger B.

Oncotarget. 2015 May 10;6(13):11395-406.

11.

The VHL-dependent regulation of microRNAs in renal cancer.

Neal CS, Michael MZ, Rawlings LH, Van der Hoek MB, Gleadle JM.

BMC Med. 2010 Oct 21;8:64. doi: 10.1186/1741-7015-8-64.

12.

2'-hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant renal cell carcinoma.

Nagaprashantha LD, Vatsyayan R, Singhal J, Lelsani P, Prokai L, Awasthi S, Singhal SS.

Carcinogenesis. 2011 Apr;32(4):568-75. doi: 10.1093/carcin/bgr021. Epub 2011 Feb 8.

13.

Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.

Khaliq S, Ajaz S, Firasat S, Shahid S, Hasan AS, Sultan G, Mohsin R, Hashmi A, Mubarak M, Naqvi SA, Rizvi SA, Mehdi SQ, Abid A.

Mutat Res. 2014 May-Jun;763-764:45-52. doi: 10.1016/j.mrfmmm.2014.03.008. Epub 2014 Apr 12.

PMID:
24727139
14.

Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.

Sourbier C, Srivastava G, Ghosh MC, Ghosh S, Yang Y, Gupta G, Degraff W, Krishna MC, Mitchell JB, Rouault TA, Linehan WM.

Oncotarget. 2012 Nov;3(11):1472-82.

15.

The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.

Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Vasselli JR, Stetler-Stevenson WG, Kaelin WG Jr, Linehan WM, Klausner RD, Gnarra JR, Vande Woude GF.

Mol Cell Biol. 1999 Sep;19(9):5902-12.

17.

Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.

Cancer Res. 2002 Jul 1;62(13):3803-11. Erratum in: Cancer Res. 2015 Sep 15;75(18):3993.

18.

von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas.

Yi Y, Mikhaylova O, Mamedova A, Bastola P, Biesiada J, Alshaikh E, Levin L, Sheridan RM, Meller J, Czyzyk-Krzeska MF.

Clin Cancer Res. 2010 Nov 1;16(21):5142-52. doi: 10.1158/1078-0432.CCR-09-3416. Epub 2010 Oct 26.

19.

Targeting von Hippel-Lindau pathway in renal cell carcinoma.

Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ.

Clin Cancer Res. 2006 Dec 15;12(24):7215-20. Review.

20.

TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.

Shang D, Liu Y, Yang P, Chen Y, Tian Y.

Urology. 2012 Apr;79(4):966.e1-7. doi: 10.1016/j.urology.2011.12.011. Epub 2012 Feb 15.

PMID:
22341602

Supplemental Content

Support Center